Eszopiclone + Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Insomnia
Conditions
Primary Insomnia
Trial Timeline
Dec 1, 2006 → Dec 1, 2008
NCT ID
NCT00414037About Eszopiclone + Placebo
Eszopiclone + Placebo is a approved stage product being developed by Sumitomo Pharma for Primary Insomnia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00414037. Target conditions include Primary Insomnia.
What happened to similar drugs?
20 of 20 similar drugs in Primary Insomnia were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01102270 | Phase 1 | Completed |
| NCT00645944 | Pre-clinical | Completed |
| NCT00826111 | Approved | Completed |
| NCT00414037 | Approved | Terminated |
| NCT00386334 | Approved | Completed |
| NCT00833547 | Pre-clinical | Completed |
| NCT00392041 | Approved | Completed |
| NCT00365976 | Approved | Completed |
| NCT00555750 | Pre-clinical | Completed |
| NCT00374192 | Pre-clinical | Completed |
| NCT00368056 | Phase 3 | Completed |
| NCT00368160 | Phase 1 | Completed |
| NCT00367965 | Phase 3 | Completed |
| NCT00366093 | Phase 3 | Completed |
| NCT00352144 | Phase 3 | Completed |
| NCT00685269 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Insomnia